|

Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG

RECRUITINGPhase 2Sponsored by Rohto Pharmaceutical Co., Ltd.
Actively Recruiting
PhasePhase 2
SponsorRohto Pharmaceutical Co., Ltd.
Started2026-04-28
Est. completion2028-09-30
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07192211

Summary

ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Patients clinically diagnosed with chronic heart failure due to ischemic heart disease who undergo CABG
2. Patients with an LVEF of less than 40% as determined by the cardiac ultrasound at the screening examination.
3. Others

Exclusion Criteria:

1. Patients who have a combination of cardiovascular disease such as severe organic valvular disease.
2. Patients who have developed acute coronary syndrome within 3 months prior to obtaining consent.
3. Others

Conditions2

Heart DiseaseIschemic Heart Disease

Interventions1

Mesenchymal Stem Cell

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.